Executive Summary
On January 8, 2026, 31 US public companies filed 8-Ks revealing a surge in material definitive agreements (Item 1.01 in ~80% of filings), often paired with equity sales (Item 3.02) and financial obligations (Item 2.03), signaling widespread financing maneuvers amid potential distress pressures. While most filings are neutral, bearish outliers including delistings, material impairments, and agreement terminations highlight pockets of acute corporate stress, particularly in biotech/healthcare sectors. This cluster suggests systemic small-cap liquidity strains, with portfolio implications for avoiding dilution-heavy names and monitoring for bankruptcy cascades.
Tracking the trend? Catch up on the prior US Corporate Distress Financial Stress SEC Filings digest from January 06, 2026.
Investment Signals(5)
- ▲
Multiple delistings and listing failures indicate severe liquidity distress [BEARISH] - SRx Health Solutions, urban-gro
- ▲
Material impairments and exit costs signal asset write-downs and restructuring [BEARISH] - HNI CORP, ImmuCell Corp
- ▲
Agreement terminations across firms point to failed partnerships or deals [BEARISH] - Sky Quarry, Alaunos Therapeutics, Neuphoria Therapeutics
- ▲
Prevalent unregistered equity sales suggest dilution to fund operations [BEARISH] - Curis, Century Therapeutics, Beneficient, Netcapital, others
- ▲
High volume of new material agreements could enable turnarounds if strategic [BULLISH] - Terreno Realty, Catheter Precision, Spruce Biosciences
Risk Flags(4)
- ▼
Delisting notices (Item 3.01) erode liquidity and investor confidence, accelerating distress spirals - SRx Health, urban-gro
- ▼
Material impairments (Item 2.06) and exit costs (Item 2.05) reflect deteriorating asset values and operational cuts - HNI CORP, ImmuCell
- ▼
Frequent terminations of material agreements (Item 1.02) combined with equity issuances indicate failed strategies and capital raises under duress
- ▼
Undisclosed details in multi-item filings amplify uncertainty, masking deeper balance sheet risks across small caps
Opportunities(4)
- ◆
Strategic material agreements (Item 1.01) in undervalued small caps could catalyze M&A or financing relief post-review of exhibits - Century Therapeutics, Spruce Biosciences
- ◆
Short opportunities in delisting-threatened names with high short interest potential - urban-gro, SRx Health Solutions
- ◆
Distressed biotech/health names with new financings offer turnaround alpha if impairments are one-offs - Catheter Precision, KALA BIO
- ◆
Portfolio hedges via puts on biotech/health indices amid clustered distress signals
Sector Themes(3)
- ◆
Biotech/healthcare dominance (~40% of filings) with equity dilutions, terminations, and impairments signaling sector-wide funding crunch and pipeline risks
- ◆
Small-cap financing frenzy via undisclosed debt/equity deals points to broad liquidity stress beyond explicit bankruptcies
- ◆
Cross-sector restructuring (real estate, energy, fintech) via impairments/exits hints at macroeconomic pressures amplifying corporate vulnerabilities
Watch List(4)
- 👁
SRx Health Solutions, urban-gro - Delisting risks could trigger rapid price declines and OTC trading illiquidity
- 👁
HNI CORP, ImmuCell Corp - Monitor impairment magnitudes and Q4 earnings for deeper operational distress
- 👁
Biotech cluster (Alaunos, Sky Quarry, Neuphoria) - Track agreement details/exhibits for termination ripple effects on peers
- 👁
High-volume Item 1.01 filers (Terreno Realty, Williams Companies) - Review exhibits for dilution scale and strategic upside
Filing Analyses(31)
08-01-2026
Terreno Realty Corp filed a Form 8-K on January 8, 2026 (AccNo: 0001193125-26-006930), reporting entry into a material definitive agreement under Item 1.01 and creation of a direct financial obligation or off-balance sheet arrangement under Item 2.03, with financial statements and exhibits under Item 9.01. No specific details on the transaction, parties, dollar values, or other quantitative metrics are disclosed in the provided filing summary. This is a multi-item mandatory disclosure of a material event.
08-01-2026
Curis Inc filed a Form 8-K on January 8, 2026 (AccNo: 0001108205-26-000002, Size: 1 MB), reporting events under Items 1.01 (Entry into a Material Definitive Agreement), 3.02 (Unregistered Sales of Equity Securities), 5.03 (Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no transaction values, share counts, financial metrics, named parties, or other quantitative details disclosed in the provided information.
08-01-2026
Neuphoria Therapeutics Inc. filed a Form 8-K on January 8, 2026 (AccNo: 0001213900-26-002245, size 293 KB), reporting under Item 1.01 entry into a material definitive agreement and under Item 1.02 termination of a material definitive agreement, with financial statements and exhibits under Item 9.01. No details on the agreements, parties, values, or impacts are disclosed. This is a multi-item mandatory filing as a material event.
08-01-2026
Catheter Precision, Inc. filed a Form 8-K on January 8, 2026 (AccNo: 0001437749-26-000839, Size: 287 KB), reporting under Item 1.01 entry into a material definitive agreement and under Item 2.03 creation of a direct financial obligation or off-balance sheet arrangement. Item 9.01 includes financial statements and exhibits. No specific transaction details, dollar values, parties, or other terms are disclosed.
08-01-2026
Century Therapeutics, Inc. filed a Form 8-K on January 8, 2026 (AccNo: 0001104659-26-001952, Size: 7 MB), reporting entry into a material definitive agreement (Item 1.01), unregistered sales of equity securities (Item 3.02), Regulation FD disclosure (Item 7.01), and financial statements/exhibits (Item 9.01). This is a multi-item mandatory filing with no specific transaction details, dollar values, share counts, or other numerical data disclosed in the provided summary. Sector is not specified.
08-01-2026
Spruce Biosciences, Inc. filed a Form 8-K on January 08, 2026 (AccNo: 0001193125-26-007038, Size: 1 MB), reporting multiple items including entry into a material definitive agreement (Item 1.01), results of operations and financial condition (Item 2.02), creation of a direct financial obligation (Item 2.03), unregistered sales of equity securities (Item 3.02), Regulation FD disclosure (Item 7.01), and financial statements/exhibits (Item 9.01). This is a multi-item filing with no specific transaction details, dollar values, or financial metrics disclosed in the provided summary. Sector not specified.
08-01-2026
Limitless X Holdings Inc. filed a Form 8-K on January 08, 2026 (AccNo: 0001493152-26-000895), reporting under Items 1.01 (Entry into a Material Definitive Agreement), 3.02 (Unregistered Sales of Equity Securities), 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers), and 9.01 (Financial Statements and Exhibits). This is a multi-item mandatory disclosure with no specific transaction values, share counts, dollar amounts, or named entities beyond the filer disclosed. Sector is not specified.
08-01-2026
Beneficient filed a Form 8-K on January 8, 2026 (AccNo: 0001493152-26-000893, Size: 10 MB) as a multi-item disclosure covering Item 3.02 (Unregistered Sales of Equity Securities), Item 3.03 (Material Modifications to Rights of Security Holders), Item 5.03 (Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). No specific transaction details, dollar values, share counts, or other quantitative metrics are disclosed in the provided filing summary. This appears to be a mandatory multi-item filing related to equity transactions and corporate governance changes.
08-01-2026
Alaunos Therapeutics, Inc. filed a Form 8-K on January 08, 2026 (AccNo: 0001193125-26-007054, Size: 580 KB), reporting under Item 1.02 termination of a material definitive agreement, Item 3.03 material modifications to rights of security holders, Item 8.01 other events, and Item 9.01 financial statements and exhibits. No specific details on the events, transaction values, or financial impacts are provided in the summary. Sector is not specified.
08-01-2026
Sky Quarry Inc. filed a Form 8-K on January 8, 2026 (AccNo: 0001096906-26-000041), reporting under Item 1.02 the termination of a material definitive agreement and under Item 9.01 financial statements and exhibits. No details on the agreement's parties, value, terms, or financial impact are disclosed. This represents a potentially negative event as it involves termination of something deemed material by the company.
08-01-2026
SRx Health Solutions, Inc. filed a Form 8-K on January 08, 2026 (AccNo: 0001493152-26-000926, size: 229 KB) under Item 3.01 reporting a notice of delisting or failure to satisfy a continued listing rule or standard, or transfer of listing from the US market. No financial details, transaction values, reasons for delisting, or other impacts are disclosed. Sector is not specified.
08-01-2026
HNI CORP filed a Form 8-K on January 8, 2026 (AccNo: 0001140361-26-000697, Size: 207 KB), reporting Item 2.05 Costs Associated with Exit or Disposal Activities, Item 2.06 Material Impairments, and Item 9.01 Financial Statements and Exhibits. This is a multi-item mandatory disclosure of potentially negative events involving restructuring costs and asset impairments. No specific dollar values, transaction sizes, or quantitative financial impacts are disclosed.
08-01-2026
TruBridge, Inc. filed a Form 8-K on January 8, 2026 (AccNo: 0001193125-26-007672), reporting under Item 1.01 (Entry into a Material Definitive Agreement), Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific details on the agreement, personnel changes, disclosures, or exhibits provided in the summary. All transaction values, financial metrics, and named entities beyond the filer are NOT_DISCLOSED.
08-01-2026
KALA BIO, Inc. filed a Form 8-K on 2026-01-08 (AccNo: 0001829126-26-000110, Size: 526 KB) disclosing entry into a Material Definitive Agreement under Item 1.01. Item 9.01 includes Financial Statements and Exhibits. No details on the agreement, transaction value, parties, or financial impacts are provided in the summary.
08-01-2026
Netcapital Inc. filed a Form 8-K on January 08, 2026 (AccNo: 0001493152-26-000969, Size: 16 MB), reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 3.02 (Unregistered Sales of Equity Securities), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific transaction details, dollar values, or other quantitative data disclosed in the provided summary. Sector not specified.
08-01-2026
Williams Companies, Inc. filed an 8-K on January 8, 2026 (AccNo: 0001193125-26-007722, Size: 371 KB) reporting under Item 1.01 entry into a Material Definitive Agreement and under Item 9.01 Financial Statements and Exhibits. No specific details on the agreement, transaction value, or financial impacts are disclosed in the provided summary. Sector not specified.
08-01-2026
Company filed Form 8-K on 2026-01-08 (AccNo: 0001140361-26-000721, Size: 846 KB) reporting Item 1.01 (Entry into a Material Definitive Agreement) and Item 2.03 (Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement). Item 9.01 includes Financial Statements and Exhibits. No details on transaction parties, value, terms, or impacts are disclosed in the provided information.
08-01-2026
Agenus Inc filed a Form 8-K on January 8, 2026 (AccNo: 0001193125-26-007706, Size: 142 KB), reporting Item 1.01 Entry into a Material Definitive Agreement and Item 3.03 Material Modifications to Rights of Security Holders. No details on the agreement, transaction terms, parties involved, financial values, or specific modifications are disclosed in the provided information. Sector not specified.
08-01-2026
Canopy Growth Corp filed a Form 8-K on January 08, 2026 (AccNo: 0001104659-26-002134, Size: 2 MB), reporting multiple items including Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation), Item 3.02 (Unregistered Sales of Equity Securities), Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing indicating a significant transaction involving agreements, financing, and equity issuance, but core event details, transaction values, share counts, and financial impacts are NOT_DISCLOSED. No specific numbers, named counterparties, or strategic context are provided in the summary.
08-01-2026
Acushnet Holdings Corp. filed a Form 8-K on 2026-01-08 (AccNo: 0001672013-26-000007, Size: 501 KB) reporting under Item 1.01 entry into a Material Definitive Agreement and under Item 9.01 Financial Statements and Exhibits. No details on the agreement's nature, parties, terms, value, or financial impacts are disclosed. This is a multi-item filing for a Material Event from US SEC source; sector not specified.
08-01-2026
ImmuCell Corp /DE/ filed a Form 8-K on January 8, 2026 (AccNo: 0001437749-26-000885, Size: 217 KB), reporting Items 2.02 (Results of Operations and Financial Condition), 2.06 (Material Impairments), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing disclosing material impairments alongside financial results and other events. Specific details including dollar values, transaction sizes, financial metrics, or strategic context are NOT_DISCLOSED.
08-01-2026
Company filed Form 8-K on 2026-01-08 (AccNo: 0001168165-26-000005, Size: 21 MB) reporting Item 1.01 Entry into a Material Definitive Agreement, Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, and Item 9.01 Financial Statements and Exhibits. This is a multi-item mandatory disclosure of a material event. No transaction details, values, counterparties, or financial metrics are disclosed.
08-01-2026
BION ENVIRONMENTAL TECHNOLOGIES INC filed a Form 8-K on January 08, 2026 (AccNo: 0001079973-26-000065, Size: 182 KB), reporting under Item 1.01 Entry into a Material Definitive Agreement and Item 9.01 Financial Statements and Exhibits. No details on the agreement, counterparties, financial terms, or exhibits are disclosed in the provided summary. Sector not specified.
08-01-2026
Calumet, Inc. (/DE) filed Form 8-K on January 8, 2026 (AccNo: 0001193125-26-007783, size: 410 KB), reporting Item 1.01 Entry into a Material Definitive Agreement, Item 8.01 Other Events, and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing from the US SEC source. No specific details, transaction values, or financial metrics disclosed in the provided summary.
08-01-2026
VEEA INC. filed a Form 8-K on January 08, 2026 (AccNo: 0001213900-26-002557, Size: 250 KB), reporting entry into a material definitive agreement (Item 1.01), termination of a material definitive agreement (Item 1.02), and creation of a direct financial obligation or off-balance sheet arrangement (Item 2.03), with financial statements and exhibits (Item 9.01). This is a multi-item mandatory filing with no specific details on the transactions, counterparties, or values disclosed in the provided information. Sector is not specified.
08-01-2026
Beachbody Company, Inc. filed a Form 8-K on January 08, 2026 (AccNo: 0001193125-26-007774, Size: 1 MB), reporting under Item 1.01 Entry into a Material Definitive Agreement, Item 7.01 Regulation FD Disclosure, and Item 9.01 Financial Statements and Exhibits. No specific details on the agreement, disclosures, transaction value, or financial impacts are provided in the available summary. All quantitative financial data is NOT_DISCLOSED.
08-01-2026
urban-gro, Inc. filed a Form 8-K on 2026-01-08 (AccNo: 0001213900-26-002552, Size: 194 KB) reporting under Item 3.01 a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. No specific details on the delisting trigger, financial impacts, transaction values, or sector are disclosed. This represents a material compliance event with bearish implications for liquidity and valuation.
08-01-2026
American Well Corp filed a Form 8-K on January 8, 2026 (AccNo: 0001193125-26-007807, Size: 918 KB), reporting under Item 1.01 entry into a Material Definitive Agreement and under Item 9.01 Financial Statements and Exhibits. The core event is the entry into this unspecified Material Definitive Agreement. No transaction values, financial impacts, named entities, or other quantitative details are disclosed in the provided filing summary.
08-01-2026
Janus International Group, Inc. filed a Form 8-K on January 8, 2026 (AccNo: 0001104659-26-002199, Size: 918 KB), reporting under Item 1.01 Entry into a Material Definitive Agreement, Item 7.01 Regulation FD Disclosure, and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing with no specific details on the agreement, disclosures, or exhibits provided in the summary. Sector not specified.
08-01-2026
VolitionRx Ltd filed a Form 8-K on January 8, 2026 (AccNo: 0001477932-26-000107, size 737 KB), reporting entry into a material definitive agreement (Item 1.01) and unregistered sales of equity securities (Item 3.02), with exhibits under Item 9.01. This is a multi-item mandatory filing with no specific transaction details, dollar values, or financial impacts disclosed in the provided summary. Sector not specified.
08-01-2026
Wellgistics Health, Inc. filed a Form 8-K on January 8, 2026 (AccNo: 0001493152-26-001001, size: 940 KB), reporting under Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation or Off-Balance Sheet Arrangement), Item 3.02 (Unregistered Sales of Equity Securities), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific transaction details, dollar values, or quantitative data disclosed in the provided information. Sector not specified.
Get daily alerts with 5 investment signals, 4 risk alerts, 4 opportunities and full AI analysis of all 31 filings
🇺🇸 More from United States
View all →March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Merger & Acquisition SEC Filings — March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings — March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC — March 24, 2026
US Executive Officer Management Changes SEC